SECTION 1: General aspects of vaccination§§1 A short history of vaccination 1§§2 Vaccine immunology 14§§3 The vaccine industry 33§§4 Vaccine manufacturing 44§§5 Evolution of adjuvants across the centuries 58§§6 Vaccine additives and manufacturing residuals in the United States:§§licensed vaccines 71§§7 Passive immunization 80§§8 General immunization practices 88§§SECTION 2: Licensed vaccines§§9 Adenovirus vaccines 113§§10 Anthrax vaccines 127§§11 Cholera vaccines 141§§12 Diphtheria toxoid 153§§13 Haemophilus influenzae vaccines 167§§14 Hepatitis A vaccines 183§§15 Hepatitis B vaccines 205§§16 Human papillomavirus vaccines 235§§17 Inactivated influenza vaccines 257§§18 Influenza vaccine-live 294§§19 Japanese encephalitis vaccines 312§§20 Measles vaccines 352§§21 Meningococcal vaccines 388§§22 Mumps vaccine 419§§23 Pertussis vaccines . 447§§24 Plague vaccines 493§§25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504§§26 Pneumococcal polysaccharide vaccines 542§§27 Poliovirus vaccine-inactivated . 573§§28 Poliovirus vaccine-live 598§§29 Rabies vaccines .646§§30 Rotavirus vaccines . 669§§31 Rubella vaccine 688§§32 Smallpox and vaccinia 718§§33 Tetanus toxoid 746§§34 Tick-borne encephalitis virus vaccines 773§§35 Tuberculosis vaccines 789§§36 Typhoid fever vaccines 812§§37 Varicella vaccine 837§§38 Yellow fever vaccine 870§§39 Zoster vaccine 969§§40 Combination vaccines 981§§SECTION 3: Vaccines in development and new vaccine strategies§§41 Biodefense and special pathogen vaccines 1008§§42 Therapeutic cancer vaccines 1018§§43 Cytomegalovirus vaccines 1032§§44 Dengue vaccines 1042§§45 Diarrhea caused by bacteria 1052§§46 Ebola vaccine 1060§§47 Epstein-Barr virus vaccines 1068§§48 Hepatitis C vaccines 1074§§49 Hepatitis E vaccines 1085§§50 Herpes simplex virus vaccines 1090§§51 Human immunodeficiency virus vaccines 1097§§52 Lyme disease vaccines 1122§§53 Malaria vaccines 1133§§54 Noninfectious disease vaccines 1138§§55 Respiratory syncytial virus and parainfluenza virus vaccines 1146§§56 Parasitic disease vaccines 1154§§57 Staphylococcus aureus vaccines 1161§§58 Streptococcus group A vaccines 1169§§59 Streptococcus group B vaccines 1176§§60 Technologies for making new vaccines 1182§§61 Alternative vaccine delivery methods 1200§§62 The development of gene-based vectors for immunization 1232§§SECTION 4: Vaccination of special groups§§63 Vaccination of immunocompromised hosts 1243§§64 Vaccination of human immunodeficiency virus-infected persons 1257§§65 Vaccines for international travel 1270§§66 Vaccines for health care personnel 1290§§SECTION 5: Public health and regulatory issues§§67 Immunization in the United States 1310§§68 Immunization in Europe . 1334§§69 Immunization in the Asia-Pacific region 1353§§70 Immunization in developing countries 1369§§71 Community immunity 1395§§72 Economic analyses of vaccine policies 1413§§73 Regulation and testing of vaccines 1427§§74 Regulation of vaccines in Europe 1447§§75 Regulation of vaccines in developing countries 1454§§76 Vaccine safety 1464§§77 Legal issues . 1481§§78 Ethics 1508§ Skryť popis